- Source: Avatrombopag
Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023.
It acts as a thrombopoietin receptor agonist.
References
Kata Kunci Pencarian:
- Avatrombopag
- ATC code B02
- Thrombopoietic agent
- Hemostatic Powder Spray TC-325
- 2-Aminothiazole
- Platelet transfusion refractoriness
